Home
report store
egfr inhibitors induced skin disorders epidemiology forecast

EGFR Inhibitors-Induced Skin Disorders Epidemiology Report

EGFR Inhibitors-Induced Skin Disorders - Epidemiology Forecast - 2036

Published Date : 2026

Pages : 60

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

EGFR Inhibitors-Induced Skin Disorders Epidemiology Insights & Trends

According to various studies it was, found that the incidence, severity, and nature of dermatologic toxicity occurring with either panitumumab or cetuximab treatment are generally similar. The most frequent Grade 1/2 skin-related toxicities that occurred in the panitumumab and cetuximab arms were skin rash (45.4% vs. 47.4%), dermatitis acneiform (24.4% vs. 24.3%), dry skin (16.5% vs. 15.7%), pruritus (i.e., severe itching; 15.9% vs. 17.3%), paronychia (9.5% vs. 12.9%), and acne (9.9% vs. 12.7%). Few patients had Grade ≥3 skin-related toxicities.
According to a study, about 50–90% of patients treated with EGFR-inhibitors develop a follicular or acneiform rash, which can be symptomatic and source of psychosocial distress, negatively impacting quality of life.
As per the secondary research, cutaneous complications are the most frequent adverse side effects of EGFR inhibitors, occurring in up to 90% of patients treated with cetuximab therapy, with grade 3–4 adverse events occurring in 11–18% of treated individuals.
Dermatologic toxicity of any grade occurs in most patients who receive anti-EGFR therapy; approximately 10% to 20% of patients experienced grade 3/4 toxicity.
The reported incidence of severe skin reactions grade 3/4 is ∼0–17%, slightly more seen in patients treated with monoclonal antibodies than in patients treated with EGFR small molecule tyrosine kinase inhibitors.

EGFR-Induced Skin Disorders Epidemiology Forecast in the United States

2025 Prevalent Cases of EGFR-Induced Skin Disorders: ~XXXX
2036 Prevalent Cases of EGFR-Induced Skin Disorders: XXXX
EGFR-Induced Skin Disorders Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘EGFR-Induced Skin Disorders Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the EGFR-Induced Skin Disorders, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period	2022–2036
Historical Year	2022–2025
Forecast Period	2026–2036
Base Year	2026
Geographies Covered	· North America : The US; · Europe: Germany, France, Italy, Spain and the UK; · Asia-Pacific: Japan
EGFR-Induced Skin Disorders Epidemiology CAGR (Study period/Forecast period)	XX% (2026-2036)
EGFR-Induced Skin Disorders Epidemiology Segmentation Analysis	Patient Burden Assesment Incident Cases of Indications Harbouring EGFR Mutation (NSCLC, CRC, Pancreatic, Head and Neck Cancer, Breast Cancer) Incident Cases of EGFR Mutation in Respective Indications Incident Cases of Treatable Population by EGFR Inhibitors Incident Cases of EGFR Inhibitors-induced Skin Disorders

EGFR-Induced Skin Disorders Understanding and Diagnosis Algorithm

EGFR-Induced Skin Disorders Overview

EGFR Inhibitor–Induced Skin Disorders are a group of dermatologic toxicities that occur as a consequence of treatment with Epidermal Growth Factor Receptor (EGFR) inhibitors, which are widely used in the management of cancers such as non-small cell lung cancer (NSCLC), colorectal cancer, head and neck cancer, pancreatic cancer, and breast cancer. EGFR plays a critical role in maintaining normal skin homeostasis, keratinocyte proliferation, epidermal differentiation, and hair follicle function. Inhibition of EGFR signaling disrupts these physiological processes, leading to cutaneous adverse events including acneiform rash, xerosis (dry skin), pruritus, eczema, paronychia, fissures, and hair abnormalities. These toxicities affect a majority of patients receiving EGFR-targeted therapies and can significantly impair quality of life, compromise treatment adherence, necessitate dose modifications, and potentially reduce the effectiveness of anticancer therapy. As the use of EGFR inhibitors continues to expand across oncology indications, the clinical burden associated with EGFR inhibitor–induced skin disorders is becoming increasingly important.

EGFR-Induced Skin Disorders Diagnosis

Diagnosis is primarily based on clinical assessment, patient history, and the temporal relationship between symptom onset and initiation of EGFR inhibitor therapy. Dermatologic evaluation typically includes assessment of rash severity, lesion distribution, extent of skin involvement, associated symptoms such as itching or pain, and the impact on daily functioning. Standardized grading systems, including the Common Terminology Criteria for Adverse Events (CTCAE), are commonly used to classify severity and guide treatment decisions. Additional investigations may be performed to exclude secondary infections or alternative dermatologic conditions when clinically indicated. Early recognition and accurate grading of skin toxicities are critical for timely intervention, minimizing treatment interruptions, maintaining adherence to cancer therapy, and improving overall patient outcomes.

Further details are provided in the report...

EGFR-Induced Skin Disorders Epidemiology

The Hemophilia epidemiology segment offers a comprehensive analysis of both historical and current patient populations, along with projected epidemiological trends across the seven major markets (7MM). It helps identify the factors influencing present and future trends through the evaluation of published research, expert opinions, and insights from key opinion leaders. Additionally, this section of the Hemophilia market report presents data on the diagnosed patient population, associated trends, and the assumptions used in forecasting disease prevalence and burden.

Key Findings from EGFR-Induced Skin Disorders Epidemiological Analysis and Forecast

Dermatologic toxicity of any grade occurs in most patients who receive anti-EGFR therapy; approximately 10% to 20% of patients experienced grade 3/4 toxicity.
The reported incidence of severe skin reactions grade 3/4 is ∼0–17%, slightly more seen in patients treated with monoclonal antibodies than in patients treated with EGFR small molecule tyrosine kinase inhibitors.
The United States holds the largest patient share of the EGFR inhibitors-induced skin disorders among the 7MM in 2025.
Among EU4 and the UK, Germany had the highest cases of EGFR inhibitors induced skin disorders followed by France and Spain in 2025.
In 2025, there were approximately 13,000 cases of EGFR inhibitors-induced skin disorders in NSCLC cases in the United States.
In 2025, highest number of cases of EGFR inhibitors-induced skin disorders was found in CRC, followed by NSCLC, and head and neck cancers in the 7MM.

Scope of the EGFR-Induced Skin Disorders Epidemiology Report

The report covers a segment of an executive summary, a descriptive overview of EGFR-Induced Skin Disorders, explaining its causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

EGFR-Induced Skin Disorders Epidemiology Report Insights

EGFR-Induced Skin Disorders Patient Population Forecast

EGFR-Induced Skin Disorders Epidemiology Report Key Strengths

Epidemiology based (epi based) Bottom up Forecasting
11-year Forecast
Patient Burden Trends (by geography)

Unlock comprehensive insights into the EGFR Inhibitors-Induced Skin Disorders market forecast through 2036, including epidemiology, emerging therapies, and growth opportunities.

FAQs Related to the EGFR-Induced Skin Disorders Epidemiology Report:

What are the disease risks, burdens, and unmet needs of EGFR-Induced Skin Disorders? What will be the growth opportunities across the 7MM concerning the patient population with EGFR-Induced Skin Disorders?
What is the historical and forecasted EGFR-Induced Skin Disorders patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy EGFR-Induced Skin Disorders Epidemiology Report

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Epidemiology

Key Findings from EGFR-Induced Skin Disorders Epidemiological Analysis and Forecast

Dermatologic toxicity of any grade occurs in most patients who receive anti-EGFR therapy; approximately 10% to 20% of patients experienced grade 3/4 toxicity.
The reported incidence of severe skin reactions grade 3/4 is ∼0–17%, slightly more seen in patients treated with monoclonal antibodies than in patients treated with EGFR small molecule tyrosine kinase inhibitors.
The United States holds the largest patient share of the EGFR inhibitors-induced skin disorders among the 7MM in 2025.
Among EU4 and the UK, Germany had the highest cases of EGFR inhibitors induced skin disorders followed by France and Spain in 2025.
In 2025, there were approximately 13,000 cases of EGFR inhibitors-induced skin disorders in NSCLC cases in the United States.
In 2025, highest number of cases of EGFR inhibitors-induced skin disorders was found in CRC, followed by NSCLC, and head and neck cancers in the 7MM.

Scope of the EGFR-Induced Skin Disorders Epidemiology Report

The report covers a segment of an executive summary, a descriptive overview of EGFR-Induced Skin Disorders, explaining its causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

EGFR-Induced Skin Disorders Epidemiology Report Insights

EGFR-Induced Skin Disorders Patient Population Forecast

EGFR-Induced Skin Disorders Epidemiology Report Key Strengths

Epidemiology based (epi based) Bottom up Forecasting
11-year Forecast
Patient Burden Trends (by geography)

FAQs Related to the EGFR-Induced Skin Disorders Epidemiology Report:

What are the disease risks, burdens, and unmet needs of EGFR-Induced Skin Disorders? What will be the growth opportunities across the 7MM concerning the patient population with EGFR-Induced Skin Disorders?
What is the historical and forecasted EGFR-Induced Skin Disorders patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy EGFR-Induced Skin Disorders Epidemiology Report

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Table of Contents

1 Key Insights

2 Report Introduction

3 Executive Summary of EGFR-Induced Skin Disorders

4 Epidemiology Forecast Methodology

5 EGFR-Induced Skin Disorders Epidemiology Overview at a Glance

5.1 Patient Share (%) Distribution by Country in 2025 in the 7MM

5.2 Patient Share (%) Distribution by Country in 2036 in the 7MM

6 EGFR-Induced Skin Disorders Disease Background and Overview

6.1 Introduction

6.2 Symptom

6.3 Transmission and Risk Factors

6.4 Pathophysiology

6.5 Diagnosis and Screening

6.5.1 Diagnostic Algorithm

6.5.2 Diagnosis Guidelines

7 EGFR-Induced Skin Disorders Epidemiology and Patient Population

7.1 Key Findings

7.2 Assumptions and Rationale

7.3 Total Incident Cases of EGFR Inhibitor–Induced Skin Disorders in the 7MM

7.4 The United States

7.4.1 Incident Cases of Indications Harbouring EGFR Mutation (NSCLC, CRC, Pancreatic, Head and Neck Cancer, Breast Cancer) in the United States

7.4.2 Incident Cases of EGFR Mutation in Respective Indications in the United States

7.4.3 Incident Cases of Treatable Population by EGFR Inhibitors in the United States

7.4.4 Incident Cases of EGFR Inhibitors-induced Skin Disorders in the United States

7.5 EU4 and the UK

7.5.1 Incident Cases of Indications Harbouring EGFR Mutation (NSCLC, CRC, Pancreatic, Head and Neck Cancer, Breast Cancer) in EU4 and the UK

7.5.2 Incident Cases of EGFR Mutation in Respective Indications in EU4 and the UK

7.5.3 Incident Cases of Treatable Population by EGFR Inhibitors in EU4 and the UK

7.5.4 Incident Cases of EGFR Inhibitors-induced Skin Disorders in EU4 and the UK

7.6 Japan

7.6.1 Incident Cases of Indications Harbouring EGFR Mutation (NSCLC, CRC, Pancreatic, Head and Neck Cancer, Breast Cancer) in Japan

7.6.2 Incident Cases of EGFR Mutation in Respective Indications in Japan

7.6.3 Incident Cases of Treatable Population by EGFR Inhibitors in Japan

7.6.4 Incident Cases of EGFR Inhibitors-induced Skin Disorders in Japan

8 KOL Views of EGFR Inhibitors-induced Skin Disorders

9 Patient Journey of EGFR Inhibitors-induced Skin Disorders

10 Appendix

10.1 Bibliography

10.2 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables:

List of Tables

Table 1: EGFR Inhibitors-Induced Skin Disorders Epidemiology in 7MM (2022-2036)

Table 2: EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in 7MM (2022-2036)

Table 3: EGFR Inhibitors-Induced Skin Disorders Epidemiology in the United States (2022-2036)

Table 4: EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in the United States (2022-2036)

Table 5: EGFR Inhibitors-Induced Skin Disorders Epidemiology in Germany (2022-2036)

Table 6: EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in Germany (2022-2036)

Table 7: EGFR Inhibitors-Induced Skin Disorders Epidemiology in France (2022-2036)

Table 8: EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in France (2022-2036)

Table 9: EGFR Inhibitors-Induced Skin Disorders Epidemiology in Italy (2022-2036)

Table 10: EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in Italy (2022-2036)

Table 11: EGFR Inhibitors-Induced Skin Disorders Epidemiology in Spain (2022-2036)

Table 12: EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in Spain (2022-2036)

Table 13: EGFR Inhibitors-Induced Skin Disorders Epidemiology in the United Kingdom (2022-2036)

Table 14: EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in the United Kingdom (2022-2036)

Table 15: EGFR Inhibitors-Induced Skin Disorders Epidemiology in Japan (2022-2036)

Table 16: EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in Japan (2022-2036)

List of Figures:

List of Figures

Figure 1 EGFR Inhibitors-Induced Skin Disorders Epidemiology in 7MM (2022-2036)

Figure 2 EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in 7MM (2022-2036)

Figure 3 EGFR Inhibitors-Induced Skin Disorders Epidemiology in the United States (2022-2036)

Figure 4 EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in the United States (2022-2036)

Figure 5 EGFR Inhibitors-Induced Skin Disorders Epidemiology in Germany (2022-2036)

Figure 6 EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in Germany (2022-2036)

Figure 7 EGFR Inhibitors-Induced Skin Disorders Epidemiology in France (2022-2036)

Figure 8 EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in France (2022-2036)

Figure 9 EGFR Inhibitors-Induced Skin Disorders Epidemiology in Italy (2022-2036)

Figure 10 EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in Italy (2022-2036)

Figure 11 EGFR Inhibitors-Induced Skin Disorders Epidemiology in Spain (2022-2036)

Figure 12 EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in Spain (2022-2036)

Figure 13 EGFR Inhibitors-Induced Skin Disorders Epidemiology in the United Kingdom (2022-2036)

Figure 14 EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in the United Kingdom (2022-2036)

Figure 15 EGFR Inhibitors-Induced Skin Disorders Epidemiology in Japan (2022-2036)

Figure 16 EGFR Inhibitors-Induced Skin Disorders Diagnosed and Treatable Cases in Japan (2022-2036)

*The table of contents is not exhaustive; will be provided in the final report

Related Reports

EGFR Inhibitors-Induced Skin Disorders - Market Insight, Epidemiology And Market Forecast - 2036

DelveInsight's EGFR Inhibitors Induced Skin Disorders Market Report 2036 offers an in-depth understanding of the disease, epidemiology, market trends in 7MM.

License Type

Offer